7 articles
Antitumor Drug Screening Assays
Antitumor drug screening assays are laboratory methods for testing how well anticancer drugs and biologic inhibitors work, ranking candidate compounds before toxicology studies or clinical trials.
Cell Migration Assays, Leukocyte
Leukocyte cell migration assays, including the Boyden/transwell filter assay, under-agarose, Zigmond and Dunn chambers, and microfluidic devices, measure white blood cell chemotaxis, chemokinesis, and haptotaxis in vitro.
Immunologic Cytotoxicity Tests
Immunologic cytotoxicity tests are laboratory assays showing how lymphocytes, antibodies, or complement damage target cells, covering cell-mediated killing assays and antibody-mediated crossmatches used to prevent transplant rejection.
Immunologic Monitoring
Immunologic monitoring (immune monitoring, MeSH D015166): testing of immune status in diagnosis and therapy of cancer, immunodeficiency, autoimmune disease, and transplantation, using humoral assays, flow and mass cytometry, and functional T-cell assays.
Leukocyte Adherence Inhibition Test
Leukocyte Adherence Inhibition Test (LAI test), an in vitro assay of cell-mediated antitumor immunity first described by Halliday in 1972, in which cancer patients' leukocytes lose glass adherence when exposed to matching tumor extracts, mediated by LAIF and blocked by serum.
Skin Window Technique
The Skin Window Technique, also known as the Rebuck Skin Window Technique, is a lab method developed by John W. Rebuck to study cellular migration during immune reactions since 1955.
Tumor Stem Cell Assay
Tumor Stem Cell Assay (tumor clonogenic assay, HTCA): soft-agar technique measuring tumor stem cell colony formation to test anticancer drugs in vitro; predicts resistance (~90%) far better than sensitivity (~57-62%).